Overview Neuropathic Pain in Patients With Cancer Status: Completed Trial end date: 2009-04-01 Target enrollment: Participant gender: Summary The purpose of this study is to collect beginning information on whether intravenous (IV) administration of KRN5500 is safe and effective for treatment of neuropathic pain in patients with cancer. Phase: Phase 2 Details Lead Sponsor: DARA TherapeuticsTreatments: KRN 5500